Clear Skies on the Horizon for Amgen’s Planned Acquisition

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • Amgen Inc. is settling challenges by six Democratic AGs and the FTC to its proposed acquisition of Horizon Therapeutics plc.
  • As we previously reported, the AGs and the FTC alleged that the acquisition was anticompetitive, as it would allow Amgen to leverage its large market share to foreclose competition against certain Horizon Therapeutic treatments for two autoimmune diseases: thyroid eye disease (TED) and chronic refractory gout (CRG).
  • The settlement agreement prohibits Amgen from using bundling or rebates to disadvantage competitors to Horizon Therapeutic’s TED and CRG drugs, and requires Amgen to obtain FTC approval if it seeks to acquire any products or interests in businesses engaged in treatment of TED or CRG, among other things.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide